Read by QxMD icon Read

Gastric Cancer

Raito Asaoka, Taiichi Kawamura, Rie Makuuchi, Tomoyuki Irino, Yutaka Tanizawa, Etsuro Bando, Masanori Terashima
BACKGROUND: Hospital readmission is gathering greater attention as a measure of health care quality. The introduction of fast-track surgery has led to shorter lengths of hospitalization without increasing the risk of postoperative complications and readmission. The collection of comprehensive readmission data is essential for the further improvement of patient care. The aim of the present study is to evaluate the risk factors for readmission within 30 days of discharge after gastrectomy...
July 13, 2018: Gastric Cancer
Jian-Xian Lin, Jun-Peng Lin, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ruhong Tu, Chao-Hui Zheng, Chang-Ming Huang, Ping Li
BACKGROUND: The systemic inflammation score (SIS), based on preoperative serum albumin (Alb) level and lymphocyte-to-monocyte ratio (LMR), has been shown to be a novel prognostic score for some tumors. We investigate the prognostic value of the SIS in patients with resectable gastric cancer (GC). METHODS: Patients with GC who underwent curative resection between December 2008 and December 2013 were included. Time-dependent receiver operating characteristics analysis (t-ROC), concordance index (C-index) and AUC were used to compare the prognostic impact...
July 7, 2018: Gastric Cancer
Yasuhiro Mitsui, Reiko Yokoyama, Shota Fujimoto, Kaizo Kagemoto, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Yoshimi Bando, Hidetaka Eguchi, Yasushi Okazaki, Hideyuki Ishida, Tetsuji Takayama
A 48-year-old Japanese female with left hypochondralgia presented at our hospital. Esophagogastroduodenoscopy (EGD) revealed gastric cancers and carpeting fundic gland polyposis (FGPs) without Helicobacter pylori infection. Computed tomography showed multiple liver metastases. Total colonoscopy revealed a colonic tubular adenoma but not polyposis. She was diagnosed as having advanced gastric cancer with liver metastasis and received chemotherapy. Her mother had died from gastric cancer, and her elderly brother and niece had FGPs as revealed by EGD...
July 2, 2018: Gastric Cancer
Yasuhiro Oono, Takeshi Kuwata, Kenji Takashima, Kensuke Shinmura, Keisuke Hori, Yusuke Yoda, Hiroaki Ikematsu, Kohei Shitara, Takahiro Kinoshita, Tomonori Yano
BACKGROUND: Receptor tyrosine kinases (RTKs) play critical roles in gastric cancer (GC) progression and are potential targets for novel molecular-targeted agents or photo-immunotherapies. During patient selection, targeted biopsy is the first step. However, heterogeneous expression of RTKs based on the macroscopic appearance in GC has not been extensively addressed. Accordingly, in this study, we evaluated differences in RTK expression associated with macroscopic appearance in GC. METHODS: In total, 375 consecutive patients who had undergone gastrectomy at the National Cancer Center Hospital East and who had histologically proven adenocarcinoma, available archived tumor sample, and no history of chemotherapy were enrolled in this study...
June 27, 2018: Gastric Cancer
Boldbaatar Gantuya, Khasag Oyuntsetseg, Dashdorj Bolor, Yansan Erdene-Ochir, Ruvjir Sanduijav, Duger Davaadorj, Tegshee Tserentogtokh, Tomohisa Uchida, Yoshio Yamaoka
BACKGROUND: Mongolia has the highest mortality rate of gastric cancer. The early detection of cancer and down-staging screening for high risk patients are essential. Therefore, we aimed to validate serum markers for stratifying patients for further management. METHODS: Endoscopy and histological examination were performed to determine high risk and gastric cancer patients. Rapid urease test, culture and histological tests were performed to diagnose Helicobacter pylori infection...
June 22, 2018: Gastric Cancer
Younghoon Kim, Xianyu Wen, Seorin Jeong, Nam-Yun Cho, Woo Ho Kim, Gyeong Hoon Kang
BACKGROUND: L1 and SAT-α are repetitive DNA elements that undergo demethylation in association with cancerization. Unlike L1 hypomethaylation, nothing is known regarding the prognostic implication of SAT-α hypomethylation alongside L1 hypomethaylaton in gastric cancers. METHODS: Formalin-fixed paraffin-embedded samples from 492 cases of advanced gastric cancer were analyzed to determine their L1 and SAT-α methylation status using pyrosequencing methylation assay...
June 20, 2018: Gastric Cancer
Raghav Sundar, Aditi Qamra, Angie Lay Keng Tan, Shenli Zhang, Cedric Chuan Young Ng, Bin Tean Teh, Jeeyun Lee, Kyoung-Mee Kim, Patrick Tan
BACKGROUND: Epstein-Barr virus-associated gastric cancer (EBVaGC) has traditionally been associated with high expression of PD-L1 and immune infiltration. Correlations between PD-L1 and other immune-related gene (IRG) expressions in EBVaGC have not been previously described. METHODS: We performed NanoString® transcriptomic profiling and PD-L1 immunohistochemistry (IHC) (using the FDA approved Dako PD-L1 IHC 22C3) on EBVaGC samples from gastric cancer patients undergoing primary tumor resections at Samsung Medical Centre, South Korea...
June 18, 2018: Gastric Cancer
Chenguang Bai, Xiaohong Liu, Cen Qiu, Jianming Zheng
BACKGROUND: FoxM1 plays important regulatory roles in a variety of diseases. However, the functional role of FoxM1 and mechanisms responsible for its expression in gastrointestinal stromal tumor (GIST) is not thoroughly understood. METHODS: FoxM1 protein expression and biological function were examined in human GIST tissues and cells using immunohistochemistry, quantitative real-time PCR, western blot, CCK-8, wound-healing- and Matrigel invasion assays, respectively...
June 15, 2018: Gastric Cancer
Yosuke Kano, Manabu Ohashi, Naoki Hiki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Yasuo Tsuda, Yoshiaki Shoji, Itaru Yasufuku, Kojiro Eto, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Takeshi Sano
In the original publication of this article, the 5-year OS rates of the S-1 group in the ACTS-GC according to TNM-6 were described incorrectly in Table 4. The revised Table 4 is given in this correction.
June 13, 2018: Gastric Cancer
Young Kwon Choi, Ji Yong Ahn, Hee Kyong Na, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
BACKGROUND: Little is known about the outcomes of gastric endoscopic submucosal dissection (ESD) in patients with chronic kidney disease (CKD). We compared the efficacy and safety of ESD between CKD and non-CKD patients. METHODS: From January 2005 to December 2014, 102 CKD patients underwent ESD for gastric neoplasms at a tertiary medical institution were reviewed retrospectively. A propensity score-matched control group (102 patients) was selected from non-CKD patients to compare clinical outcomes between CKD and non-CKD patients...
June 12, 2018: Gastric Cancer
Hong Jae Chon, Chan Kim, Arthur Cho, Yoo Min Kim, Su Jin Jang, Bo Ok Kim, Chan Hyuk Park, Woo Jin Hyung, Joong Bae Ahn, Sung Hoon Noh, Mijin Yun, Sun Young Rha
BACKGROUND: The prognostic impact of preoperative 18 F-FDG PET/CT in advanced gastric cancer (AGC) remains a matter of debate. This study aims to evaluate the prognostic impact of SUVmax in preoperative 18 F-FDG PET/CT of AGC according to histologic subtype, with a focus on the differences between tubular adenocarcinoma and signet ring cell (SRC) carcinoma. METHODS: As a discovery set, a total of 727 AGC patients from prospective database were analyzed according to histologic subtype with Cox proportional hazard model and p-spline curves...
June 9, 2018: Gastric Cancer
Tomohiro Nishina, Mizutomo Azuma, Kazuhiro Nishikawa, Masahiro Gotoh, Hideaki Bando, Naotoshi Sugimoto, Kenji Amagai, Keisho Chin, Yasumasa Niwa, Akihito Tsuji, Hiroshi Imamura, Masahiro Tsuda, Hirofumi Yasui, Hirofumi Fujii, Kensei Yamaguchi, Hisateru Yasui, Shuichi Hironaka, Ken Shimada, Hiroto Miwa, Terukazu Mitome, Hiroki Kageyama, Ichinosuke Hyodo
BACKGROUND: We investigated early tumor shrinkage (ETS) and depth of response (DpR) using data from the G-SOX study comparing S-1 plus oxaliplatin with S-1 plus cisplatin as the first-line treatment for advanced gastric cancer (AGC). METHODS: ETS was determined as % decrease in the sum of the longest diameters of the target lesions at the first evaluation of week 6 compared to baseline. DpR was the maximum % shrinkage during the study treatment. The impact of ETS (cutoff value 20%) and DpR (continuous value) on progression-free survival (PFS) and overall survival (OS) were assessed by the log-rank test and Cox regression analysis including prognostic factors obtained in the G-SOX study; ECOG performance status, baseline sum of tumor diameters, disease status (recurrent/unresectable), and histology (diffuse/intestinal)...
June 9, 2018: Gastric Cancer
Ji Hyun Yang, Hyunho Kim, Sang Young Roh, Myung Ah Lee, Jae Myung Park, Han Hee Lee, Cho Hyun Park, Han Hong Lee, Eun Sun Jung, Sung Hak Lee, Young Joon Lee, Moon Hyung Choi, Okran Kim, In-Ho Kim
BACKGROUND: Our goal was to evaluate changes in PD-L1 expression in primary tumours of metastatic gastric cancer before and after chemotherapy. METHODS: We evaluated the PD-L1 expression of 72 patients with primary gastric cancer, before and after palliative first-line platinum-based chemotherapy, between January 2015 and March 2017. The PD-L1 ratio was defined as pre-chemotherapy PD-L1 expression divided by the post-chemotherapy PD-L1 expression. RESULTS: In 30 patients with PD-L1 negative pre-chemotherapy, 12 (40%) were positive post-chemotherapy; among the 42 patients with PD-L1 positive pre-chemotherapy, 24 (57...
June 2, 2018: Gastric Cancer
Akihito Kawazoe, Kohei Shitara, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Atsushi Ohtsu, Atsushi Ochiai, Yosuke Togashi, Hiroyoshi Nishikawa, Toshihiko Doi, Takeshi Kuwata
BACKGROUND: Recently, the U.S. Food and Drug Administration approved pembrolizumab for patients (pts) with PD-L1-positive metastatic gastric cancer (MGC) based on 22C3 immunohistochemistry (IHC) assay. However, little is known about detailed clinicopathological features of 22C3 PD-L1 expression in MGC. PATIENTS AND METHODS: Pts with histologically confirmed MGC were eligible for this prospective observational study. PD-L1 expression (22C3) on tumor cell (TC) or immune cell (IC) and mismatch repair (MMR) were analyzed by IHC...
June 1, 2018: Gastric Cancer
Fei Yu, Tian Tian, Bin Deng, Tianpei Wang, Qi Qi, Meng Zhu, Caiwang Yan, Hui Ding, Jinchen Wang, Juncheng Dai, Hongxia Ma, Yanbing Ding, Guangfu Jin
BACKGROUND: Gastric cancer (GC) is one of the high-incidence and high-mortality cancers all over the world. Though genome-wide association studies (GWASs) have found some genetic loci related to GC, they could only explain a small fraction of the potential pathogenesis for GC. METHODS: We used multi-marker analysis of genomic annotation (MAGMA) to analyze pathways from four public pathway databases based on Chinese GWAS data including 2631 GC cases and 4373 controls...
June 1, 2018: Gastric Cancer
Atsuo Takashima, Kohei Shitara, Kazumasa Fujitani, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hirofumi Fujii, Kei Muro, Taito Esaki, Yasuhiro Choda, Toshimi Takano, Keisho Chin, Atsushi Sato, Masahiro Goto, Norimasa Fukushima, Takuo Hara, Nozomu Machida, Manabu Ohta, Narikazu Boku, Masashi Shimura, Satoshi Morita, Wasaburo Koizumi
BACKGROUND: In the ABSOLUTE trial, weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) showed non-inferiority to weekly solvent-based paclitaxel (w-sb-PTX) for overall survival (OS). Thus, w-nab-PTX might be an option for second-line chemotherapy in advanced gastric cancer (AGC). However, predictive factors for efficacies of these agents have not been evaluated. METHODS: Patients previously enrolled in the ABSOLUTE trial were divided into apparent peritoneal metastasis group (PM group) and no apparent peritoneal metastasis group (no PM group) based on baseline imaging evaluated by RECIST ver...
May 31, 2018: Gastric Cancer
Gian Luca Baiocchi, Simone Giacopuzzi, Daniele Marrelli, Daniel Reim, Guillaume Piessen, Paulo Matos da Costa, John V Reynolds, Hans-Joachim Meyer, Paolo Morgagni, Ines Gockel, Lucio Lara Santos, Lone Susanne Jensen, Thomas Murphy, Shaun R Preston, Mikhail Ter-Ovanesov, Uberto Fumagalli Romario, Maurizio Degiuli, Wojciech Kielan, Stefan Mönig, Piotr Kołodziejczyk, Wojciech Polkowski, Richard Hardwick, Manuel Pera, Jan Johansson, Paul M Schneider, Wobbe O de Steur, Suzanne S Gisbertz, Henk Hartgrink, Joanna W van Sandick, Nazario Portolani, Arnulf H Hölscher, Maristella Botticini, Franco Roviello, Christophe Mariette, William Allum, Giovanni De Manzoni
BACKGROUND: Perioperative complications can affect outcomes after gastrectomy for cancer, with high mortality and morbidity rates ranging between 10 and 40%. The absence of a standardized system for recording complications generates wide variation in evaluating their impacts on outcomes and hinders proposals of quality-improvement projects. The aim of this study was to provide a list of defined gastrectomy complications approved through international consensus. METHODS: The Gastrectomy Complications Consensus Group consists of 34 European gastric cancer experts who are members of the International Gastric Cancer Association...
May 30, 2018: Gastric Cancer
Masashi Takeuchi, Hiroya Takeuchi, Hirofumi Kawakubo, Ayako Shimada, Tadaki Nakahara, Shuhei Mayanagi, Masahiro Niihara, Kazumasa Fukuda, Rieko Nakamura, Koichi Suda, Norihito Wada, Yuko Kitagawa
BACKGROUND: Sentinel node (SN) concept is being applied to early gastric cancer. However, when SNs are positive for metastasis, it is unclear how often LNs in other LN basins show metastasis. We aimed to investigate LN metastasis possibility in LN basins without SNs (non-SN basins). We determined risk factors for metastasis in non-SN basins and identified a prediction model for non-SN basin metastasis using classification and regression tree (CART) analysis. METHODS: We enrolled 550 patients who were diagnosed with cT1N0M0 or cT2N0M0 gastric cancer with a single lesion and underwent SN mapping...
May 24, 2018: Gastric Cancer
Toshiyuki Tanahashi, Kazuhiro Yoshida, Kazuya Yamaguchi, Naoki Okumura, Atsushi Takeno, Kazumasa Fujitani, Norimasa Fukushima, Nobuhiro Takiguchi, Yasunori Nishida, Narikazu Boku, Takaki Yoshikawa, Masanori Terashima
BACKGROUND: In Japan, S-1 adjuvant chemotherapy for 1 year is the standard of care for the treatment of stage II and III patients under 80 years old with gastric cancer after curative operation. However, the feasibility of S-1 chemotherapy in patients over 80 years old has not yet been elucidated. METHODS: To clarify the current treatment situation and feasibility of S-1 treatment in patients over 80 years old, a questionnaire survey of the patients treated from January 2011 to December 2012 was conducted at 58 member institutions of the Stomach Cancer Study Group of the JCOG (Japan Clinical Oncology Group)...
May 24, 2018: Gastric Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"